Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Asthma
Phase PHASE4
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Albuterol Sulfate — Visit 1: Albuterol Sulfate (90mcg) two puffs will be administered via metered-dose inhaler (MDI) with spacer during the baseline study visit to obtain baseline imaging values.
  • Drug: Albuterol-Budesonide — Visit 2: AIRSUPRA (Albuterol/Budesonide) (90mcg/80mcg) two puffs will be administered via MDI with spacer during this study visit. This intervention is used to evaluate its effect on ventilation defect percentage (VDP), ventilation heterogeneity (VH), and perfusion metrics derived from XV LVAS imaging

Primary Outcomes

  • Change in Regional Ventilation (Baseline, 30 minutes after budesonide administration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-04-27
Completion: 2028-04
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Miami
Collaborators: Australian Lung Health Initiative Pty Ltd
Principal Investigators:
  • Trishul Siddharthan, MD (PRINCIPAL_INVESTIGATOR) - University of Miami
Contact Information
Study Contact:
Maria McCoy
305-243-2568
mcm456@med.miami.edu
Sonia Dipti Meena Velmurugan, MS
305-243-2568
sxm3597@med.miami.edu
Tiffany Salcito
305-243-2568
tns93@med.miami.edu
University of Miami - Converge Miami
Interventions
  • Drug: Albuterol Sulfate — Visit 1: Albuterol Sulfate (90mcg) two puffs will be administered via metered-dose inhaler (MDI) with spacer during the baseline study visit to obtain baseline imaging values.
  • Drug: Albuterol-Budesonide — Visit 2: AIRSUPRA (Albuterol/Budesonide) (90mcg/80mcg) two puffs will be administered via MDI with spacer during this study visit. This intervention is used to evaluate its effect on ventilation defect percentage (VDP), ventilation heterogeneity (VH), and perfusion metrics derived from XV LVAS imaging
Study Locations (1 sites)
University of Miami - Converge Miami, Miami, Florida 33136 United States
Eligibility Criteria
Inclusion Criteria: * Physician diagnosis of asthma * Baseline Forced Expiratory Volume in 1 Second (FEV1) \< 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry * Adults, 18-75 years of age * Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment Exclusion Criteria: * Current cigarette smoking or a past history of \>10 pack-year smoking * Current nicotine vaping * Pregnant and breast-feeding women * Respiratory infection within 4 weeks of proposed study date * Forced Expiratory Volume in 1 Second (FEV1) \< 50% * Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance * Use of beta-blockers * Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.
Conditions Severe Asthma, Asthma Control Level
Phase Not Applicable
Enrollment 230
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to determine the prevalence of remission among adults with severe asthma, as well as the factors associated with remission in Thailand. The main question the study aims to answer is: What is the prevalence of remission among adults with severe asthma in Thailand? Participants will complete questionnaires on asthma symptoms and undergo pulmonary function testing and a blood test once.

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires — GINA and ACT are questionnaires used to assess the level of asthma control.
  • Diagnostic Test: Spirometry — Spirometry is a tool used to assess pulmonary function.
  • Diagnostic Test: Fractional exhaled nitric oxide (FeNO) test — FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
  • Diagnostic Test: Blood eosinophil count (BEC) — BEC is a tool used to assess eosinophilic inflammation and asthma remission.

Primary Outcomes

  • Prevalence rate of severe asthma remission (The beginning of the study)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-01
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 230 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thammasat University
Principal Investigators:
  • Narongkorn Saiphoklang (PRINCIPAL_INVESTIGATOR) - Thammasat University Faculty of Medicine
Contact Information
Study Contact:
Narongkorn Saiphoklang, MD
+6629269794
M_narongkorn@hotmail.com
Pacharaporn Tangsathapornpong, MD
+6629269701
pacharaporn.kaimook@gmail.com
Narongkorn Saiphoklang, MD
+6629269794
M_narongkorn@hotmail.com
Narongkorn Saiphoklang
Interventions
  • Other: Global Initiative for Asthma (GINA) and Asthma Control Test (ACT) questionnaires — GINA and ACT are questionnaires used to assess the level of asthma control.
  • Diagnostic Test: Spirometry — Spirometry is a tool used to assess pulmonary function.
  • Diagnostic Test: Fractional exhaled nitric oxide (FeNO) test — FeNO is a tool used to assess eosinophilic airway inflammation and asthma remission.
  • Diagnostic Test: Blood eosinophil count (BEC) — BEC is a tool used to assess eosinophilic inflammation and asthma remission.
Study Locations (1 sites)
Narongkorn Saiphoklang, Pathum Thani, 12120 Thailand
Eligibility Criteria
Inclusion Criteria: * severe asthma * age 18 years or older Exclusion Criteria: * inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test
Conditions Asthma
Phase PHASE3
Enrollment 480
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of the study is to evaluate the efficacy and safety of 610 in Chinese adults with severe asthma.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Drug: 610 — 610 subcutaneously injection.
  • Drug: Placebo — Placebo subcutaneously injection.

Primary Outcomes

  • Annualized rate of severe exacerbation events (Up to 52 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-06-24
Completion: 2027-09
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 480 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Principal Investigators:
  • Min Zhang (PRINCIPAL_INVESTIGATOR) - Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
  • Xin Zhou (PRINCIPAL_INVESTIGATOR) - Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact Information
Study Contact:
Qinghong Zhou, MD
+86 18911301578
zhouqinghong@3sbio.com
Interventions
  • Drug: 610 — 610 subcutaneously injection.
  • Drug: Placebo — Placebo subcutaneously injection.
Study Locations (1 sites)
Shanghai General Hospital, Shanghai, Shanghai Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Able to give written informed consent prior to participation in the study. 2. Male or female adults ages 18 to 75 years old when signing the informed consent. 3. Documented diagnosis of asthma for at least one year prior to screening. 4. History of physician-diagnosed asthma requiring treatment with ICS and at least one other control medication for at least 6 months prior to screening. Exclusion Criteria: 1. Presence of a known pre-existing, clinically important lung condition other than asthma. 2. Severe asthma exacerbation within 4 weeks prior to randomization. 3. Subjects with any eosinophilic diseases other than asthma. 4. Known, pre-existing severe or clinically significant cardiovascular disease. 5. known, pre-existing other concurrent clinically significant medical conditions that are uncontrolled with standard treatment. 6. Subjects who have active Hepatitis B, Hepatitis C or HIV infections as determined by positive results at Screening. 7. Subjects with allergy/intolerance to a monoclonal antibody.
Conditions Asthma, Wheeze, Hypersensitivity, Endoph...
Phase Not Applicable
Enrollment 1500
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Despite its common occurrence, still little is known about pathomechanisms determining different wheeze and asthma trajectories and phenotypes in children, and those beginning in adulthood. Therefore, deciphering underlying determinants for different childhood and adult asthma phenotypes is urgently needed to develop personalized treatment approaches targeting distinct underlying mechanisms. Thereby, secondary prevention early in the disease process can also be achieved. The decoding of such mechanisms and their translation to the individual patient is the aim of the Disease Area Asthma Allergy of the 'German Centre for Lung Research' (DZL).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Prevalence of asthma (At baseline and during yearly follow-ups up to 2 years)
  • Prevalence of transient preschool wheeze (At baseline and during yearly follow-ups up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2013-01
Completion: 2027-12
Eligibility
Age: 6 Months – 18 Years
Sex: ALL
Volunteers: true
Enrollment: 1500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: LMU Klinikum
Collaborators: German Federal Ministry of Education and Research, German Center for Lung Research, Comprehensive Pulmonary Center Munich, Airway Research Center North, Biomedical Research in Endstage and Obstructive Lung Disease Hannover, Translational Lung Research Center Heidelberg, Universities of Giessen and Marburg Lung Center
Principal Investigators:
  • Bianca Schaub, MD (PRINCIPAL_INVESTIGATOR) - Klinikum der Universitaet Muenchen, Comprehensive Pulmonary Center Munich
  • Gesine Hansen, MD (PRINCIPAL_INVESTIGATOR) - Biomedical Research in Endstage and Obstructive Lung Disease Hannover
  • Folke Brinkmann, MD (PRINCIPAL_INVESTIGATOR) - Airway Research Center North
Contact Information
Study Contact:
Esther Zeitlmann, Diplom
+49894400
esther.zeitlmann@med.uni-muenchen.de
Bianca Schaub, MD
+49894400
bianca.schaub@med.uni-muenchen.de
Silke van Koningsbruggen-Rietschel, MD
+49 221 478-
Silke.vanKoningsbruggen@uk-koeln.de
University Children's Hospital Cologne, Department of Paediatric Allergology and Pneumology
Interventions
N/A
Study Locations (5 sites)
University Children's Hospital Cologne, Department of Paediatric Allergology and Pneumology, Cologne, 50937 Germany
Medizinische Hochschule Hannover, Biomedical Research in Endstage and Obstructive Lung Disease, Hanover, 30625 Germany
Universitaetsklinikum Schleswig-Holstein, Klinik für Kinder- und Jugendmedizin, Airway Research Center North, Lübeck, 23528 Germany
Klinik für Kinder- und Jugendmedizin, Universitaetsklinikum Giessen und Marburg GmbH, Universities of Giessen and Marburg Lung Center, Marburg, 35033 Germany
Klinikum der Universitaet Muenchen, Comprehensive Pulmonary Center Munich, Munich, 80337 Germany
Eligibility Criteria
Inclusion Criteria: * informed consent by parents (and by children if age \> 8 years) * age 6 months to 18 years * term delivery (≥ 37 weeks) * active/passive understanding of German * age 6 months - \< 6 years: preschool wheeze (more than two episodes of wheeze during 12 months prior to inclusion) * age at least 6 years: doctor diagnosed asthma (according to current guidelines) Exclusion Criteria: * known inborn or perinatal pulmonary disease * airway malformation * oxygen therapy after birth with a duration of more than 24 hours * ventilator support or mechanical ventilation after birth * diagnoses of cystic fibrosis; primary ciliary dyskinesia * heart failure diagnosed after birth affecting pulmonary circulation * major respiratory diseases such as e.g. interstitial lung disease * any current non-atopic comorbidity * fever of at least 38.5°C during the last two weeks prior to the planned first visit
Conditions Thyroid Eye Disease, Vasculitis, COPD Ex...
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This is a pilot study to investigate serum prednisolone profiles in: * Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting. * Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone. The study will comprise 3 groups, including those started on high doses of prednisolone acutely in an inpatient or outpatient setting, participants on chronically high doses, and those receiving a several week course of high dose methylprednisolone or dexamethasone. The study aims to measure prednisolone levels at a number of time points to investigate serum profile differences in those receiving prednisolone acutely compared with longer term steroid use. Further samples will be taken to characterise additional metabolic changes.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Interventions / Regimen

  • Other: No intervention - prednisolone is taken as part if routine clinical care. — Prednisolone given orally prior to taking timed samples for levels

Primary Outcomes

  • To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose prednisolone acutely and in the chronic setting). (Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years))
  • To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose (Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years))
  • To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose (Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years))
  • To elucidate differences in prednisolone pharmacokinetics (in patients receiving high dose (Pharmacokinetics measurements taken at the first and second visits. This will be of variable duration depending on duration of steroid treatment (5 days up to 2 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-04-12
Completion: 2030-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Imperial College London
Principal Investigators:
  • Karim Meeran, MBBS BSc MD (PRINCIPAL_INVESTIGATOR) - Imperial College London
Contact Information
Study Contact:
Katharine Lazarus, MBChB MRCP
07555717544
imperial.steroids@nhs.net
Interventions
  • Other: No intervention - prednisolone is taken as part if routine clinical care. — Prednisolone given orally prior to taking timed samples for levels
Study Locations (1 sites)
Imperial College Healthcare NHS Trust, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: * Aged 18 - 75 years * Male or female * Participants who are otherwise healthy enough to participate, as determined by pre-study medical history * Participants who are able and willing to give written informed consent to participate in the study * Group A only: Patients requiring acute (\<5 days) high dose (minimum 30mg) oral prednisolone therapy for antiinflammatory purposes in either an inpatient or outpatient setting. * Group B only: Minimum of 1 month duration of high dose prednisolone (\>30mg) if in the chronic use group. * Group C only: Patients started on high dose methylprednisolone (\>3 day course) or prolonged courses of dexamethasone. Exclusion Criteria: * Participants with a diagnosis of Type 1 or Type 2 diabetes mellitus. * Unable to give informed consent. * Taking supplements or herbal medications that the participant is unwilling or unable to stop prior to and during the study period e.g. St John's Wort (may decrease prednisolone levels), Cat's claw, Echinacea (immunomodulatory properties). * Currently taking medications that alter CYP3A4 metabolism of glucocorticoids that the participant is unwilling or unable to stop prior to and during the study period e.g. phenytoin, phenobarbital, rifampicin, rifabutin, carbamazepine, primidone, aminogluethimide, itraconazole, ketoconazole, ciclosporin or ritonavir. * Pregnancy. Females of child-bearing age will be asked to provide a urine sample for a pregnancy test at each visit. * History of any medical, psychological or other condition, or use of any medications, including over-the-counter products, which, in the opinion of the investigators, would either interfere with the study or compromise the safety of the participant.
Conditions Asthma Management, Time Restricted Eatin...
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to explore how early time-restricted eating (eTRE) - where all daily meals are eaten within a specific time window - affects health and quality of life in adults. The researchers will compare results between adults with mild, well-controlled asthma and adults without asthma (non-asthma group). Participants can continue to eat their normal food; only the timing of meals will change.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Early Time-Restricted Eating (eTRE) and Habitual Diet (HD) — The participants who are assigned to eTRE will be asked to eat from 8 am to 4 pm without restriction on the quantity or amount of food and fast for the rest of the time except for drinking water for one week. After a minimum of two weeks washout period, participants will be asked to follow their habitual diet for one week.
  • Other: Habitual Diet (HD) and Early Time-Restricted Eating (eTRE) — The participants will be asked to follow their habitual diet for one week. After a minimum of two weeks washout period, the participants will be assigned to eTRE and asked to eat from 8 am to 4 pm without restriction on the quantity or amount of food and fast for the rest of the time except for drinking water for one week.

Primary Outcomes

  • Lung Function Parameters, FEV1 in Liters (L) (At baseline and after 1 week in each study arm)
  • Lung Function Parameters, FVC in Liters (L) (At baseline and after 1 week in each study arm)
  • Lung Function Parameters, FEV1/ FVC ratio (At baseline and after 1 week in each study arm)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-02-25
Completion: 2027-07-01
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: De Montfort University
Collaborators: King Saud Bin Abdulaziz University for Health Sciences
Contact Information
Study Contact:
Nouf N Alotaibi
+447852689959
P2876983@my365.dmu.ac.uk
Nouf Alotaibi
P2876983@my365.dmu.ac.uk
Health and Life Science
Mariasole Da Boit, Phd
Health and Life Science
Interventions
  • Other: Early Time-Restricted Eating (eTRE) and Habitual Diet (HD) — The participants who are assigned to eTRE will be asked to eat from 8 am to 4 pm without restriction on the quantity or amount of food and fast for the rest of the time except for drinking water for one week. After a minimum of two weeks washout period, participants will be asked to follow their habitual diet for one week.
  • Other: Habitual Diet (HD) and Early Time-Restricted Eating (eTRE) — The participants will be asked to follow their habitual diet for one week. After a minimum of two weeks washout period, the participants will be assigned to eTRE and asked to eat from 8 am to 4 pm without restriction on the quantity or amount of food and fast for the rest of the time except for drinking water for one week.
Study Locations (1 sites)
Health and Life Science, Leicester, England United Kingdom
Eligibility Criteria
Inclusion Criteria: * Adults between 18 and 65 years old. * Non asthma group: individuals without asthma * Asthma group: Have already been diagnosed with controlled mild asthma. * Not following any diet regimen. * Able to read the information pack and give consent in English. Exclusion Criteria: * Moderate to severe asthma * Pregnant * Smoking * Systemic corticosteroids. * History of recent respiratory disease, current chest infection, and collapsed lung. * History of recent surgery (last 2 months), including thoracic, abdominal, and eye surgery. * Being diagnosed with cardiovascular diseases, e.g., unstable angina, a heart attack, uncontrolled high blood pressure, stroke, and aneurysm. * Broken ribs or neck vertebrae. * Cancer. * History of autoimmune diseases * Being diagnosed with an eating disorder. * Overnight shift work
Conditions Severe Asthma
Phase Not Applicable
Enrollment 5
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

In this study, xenon MRI will be used to evaluate regional functional consequences of mucus plugs in the lungs of patients with severe asthma. Mucus plugs will be identified using CT imaging, and xenon MRI will be used to evaluate ventilation and gas exchange impairments in regions of the lungs corresponding to the airways downstream of mucus plugs.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Combination Product: Hyperpolarized Xenon 129 — Pulmonary magnetic resonance imaging using hyperpolarized xenon-129 gas as an inhaled contrast agent

Primary Outcomes

  • Ventilation Defect in Mucus-blocked regions (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-17
Completion: 2027-09
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 5 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bastiaan Driehuys
Collaborators: University of Kansas Medical Center, Polarean, Inc.
Principal Investigators:
  • David Mummy, PhD (PRINCIPAL_INVESTIGATOR) - Duke University
Contact Information
Study Contact:
David Mummy, PhD
9846847783
david.mummy@duke.edu
Bastiaan Driehuys, PhD
919-684-7786
bastiaan.driehuys@duke.edu
Interventions
  • Combination Product: Hyperpolarized Xenon 129 — Pulmonary magnetic resonance imaging using hyperpolarized xenon-129 gas as an inhaled contrast agent
Study Locations (1 sites)
Duke University Medical Center, Durham, North Carolina 27713 United States
Eligibility Criteria
Inclusion Criteria: * Adequate completion of informed consent process with written documentation * Patients 18 - 65 years old * Physician diagnosis of asthma for \> 1 year * Able to perform reproducible spirometry according to ATS criteria based on clinical PFTs within previous 30 days of enrollment * All racial/ethnic backgrounds may participate * Blood eosinophil count \> 300 cells/μL * Smoking history \<10 pack years * No smoking history (including vapes, cigar, or marijuana use) in the last 3 months * About to initiate asthma therapy with either dupilumab, tezepelumab, or benralizumab as part of their standard of care Exclusion Criteria: * Respiratory tract infection within the 4 weeks prior to Visit 1 * Body mass index (BMI) \> 30 at Visit 1 * One-time doses such as intra-articular injections require a 4-week washout prior to Visit 1 * Asthma-related ER visit within the previous 4 weeks of Visit 1 or at any time while on the study * Significant concomitant medical illness, including (but not limited to) heart disease, cancer, uncontrolled diabetes, other chronic lung diseases (determined by the Investigator.) * Resting O2 saturation \<90% with maximum supplemental O2 delivered by nasal cannula * Positive urine pregnancy test at Visit 1 or at any time while on the study * Participation in an intervention study (including bronchoscopy) or use of investigative drugs within the past 30 days or plans to enroll in such a trial during the study * Unable or unlikely to complete study assessments in the opinion of the Investigator * Study intervention poses undue risk to patient in the opinion of the Investigator * Conditions that will prohibit MRI scanning determined by the MRI safety screening.
Conditions Depression
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The research aims to investigate the effectiveness of the therapeutic song-writing program on young people with depressive symptoms. This study adopts a multicentre randomized control trial two arms research design. A randomised controlled trial will compare a typical 7-session therapeutic song-writing program with a waitlist-control group to determine whether the 7-session therapeutic song-writing program can produce better outcomes for young people with depressive symptoms, including improvement in depressive symptoms, self-stigma, self-esteem, sense of hope and social support at post-intervention. The 7-session therapeutic song-writing program will be delivered by trained and experienced social workers and helping professionals who are familiar with music therapy. A research staff, who does not involve in the group allocation and delivery of group intervention, conduct the intervention outcomes assessment of the participants before and after the intervention. Standardized assessment tools are used to assess the intervention outcomes. The ethical considerations of this study were reviewed and approved by the Human and Artefacts Ethics Sub-Committee of the City University of Hong Kong in 2025.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: therapeutic song-writing program — The therapeutic song-writing program consists 7 session. One session will be conducted per week, with each session lasting for about 90 minutes. A social worker and a helping professional who is familiar with music therapy will be recruited to run the therapeutic song-writing program at a collaborative social service centre and school. A standardized program manual is designed by the research team. The social workers and helping professionals who run the therapeutic song-writing program will receive training and supervision on conducting the therapeutic song-writing program by the research team.
  • Behavioral: Waitlist control group — Waitlist control group will receive will receive treatment as usual provided by the collaborative centres and schools, including recreational activities and interest classes, at the initial stage and will receive the same therapeutic song-writing program at a later stage

Primary Outcomes

  • The Chinese Depression Anxiety Stress Scale-Youth (DASS-Y) (It will be used before and after the intervention (over 7-weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-17
Completion: 2027-10-31
Eligibility
Age: 13 Years – 24 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City University of Hong Kong
Collaborators: The Salvation Army, Hong Kong and Macau Command
Contact Information
Study Contact:
Kim-wan Daniel Young, PhD
+85234428954
dkwyoung@cityu.edu.hk
Young Kim-wan, PhD
34428954
dkwyoung@cityu.edu.hk
City University of Hong Kong
Interventions
  • Behavioral: therapeutic song-writing program — The therapeutic song-writing program consists 7 session. One session will be conducted per week, with each session lasting for about 90 minutes. A social worker and a helping professional who is familiar with music therapy will be recruited to run the therapeutic song-writing program at a collaborative social service centre and school. A standardized program manual is designed by the research team. The social workers and helping professionals who run the therapeutic song-writing program will receive training and supervision on conducting the therapeutic song-writing program by the research team.
  • Behavioral: Waitlist control group — Waitlist control group will receive will receive treatment as usual provided by the collaborative centres and schools, including recreational activities and interest classes, at the initial stage and will receive the same therapeutic song-writing program at a later stage
Study Locations (1 sites)
City University of Hong Kong, Kowloon Tong, Hong Kong Hong Kong
Eligibility Criteria
Inclusion Criteria: 1. aged between 13 to 24 years; 2. having mild to moderate depression and/or anxiety as assessed using a standardized assessment tool, i.e. Chinese Depression Anxiety Stress Scale-Youth (DASS-Y) with a DASS-Y Depression score between 5 and 12; 3. service users of The Salvation Army social service unit; and 4. giving informed consent to this research work. For those aged below 18, parental consent will be obtained. Exclusion Criteria: Those with severe depression (i.e. a DASS-Y Depression score ≥ 13) and/or severe anxiety (i.e. a DASS-Y Anxiety score ≥ 8) are excluded from this study.
Conditions Depression
Phase NA
Enrollment 70
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Notwithstanding the cumulative evidence on the safety and efficacy of transcranial magnetic stimulation in depression care, the non-response rate to transcranial magnetic stimulation (TMS) amongst treatment-resistant depression has remained substantial despite the health care cost and time incurred. There remains a compelling clinical need to find valid biomarkers to inform personalized treatment. Using supervised machine learning on 4 combined features of neuroimaging markers, our group recently reported excellent prediction for clinical response in 70 patients receiving TMS to left dorsolateral prefrontal cortex for medication-resistant major depression in 2015-18 (Phase 1 study).The clinical utility of these potential neuroimaging biomarkers is still uncertain without further validation of the trained model in an independent clinical cohort.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Device: rTMS group

Primary Outcomes

  • Montgomery-Ashberg Depression Rating Scale (Percentage change baseline versus week 4)
  • Montgomery-Ashberg Depression Rating Scale (Percentage change baseline versus week 6)
  • Montgomery-Ashberg Depression Rating Scale (Percentage change baseline versus week 8)
  • Montgomery-Ashberg Depression Rating Scale (Percentage change baseline versus week 12)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2015-08-04
Completion: 2026-12
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: false
Enrollment: 70 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Chinese University of Hong Kong
Principal Investigators:
  • Sau Man S Chan (PRINCIPAL_INVESTIGATOR) - Chinese University of Hong Kong
Contact Information
Study Contact:
The Department of Psychiatry
852-2607-6027
psychiatry@cuhk.edu.hk
Helene J Hopman
852-5597-1622
hjhopman@link.cuhk.edu.hk
Wing Sze Ho, M.Sc
852-6309-3272
stephy0306@hotmail.com
Department of Psychiatry, CUHK
Interventions
  • Device: rTMS group
Study Locations (1 sites)
Department of Psychiatry, CUHK, Hong Kong, 852 Hong Kong
Eligibility Criteria
Inclusion Criteria: * right-handed * meet the Diagnostic and Statistical Manual of Mental Disorder, Fourth Edition (DSM-IV) criteria for major depressive disorder * at least moderate episode or with a score of \>20 on Montgomery-asberg Depression Rating Scale (MADRS) and \>18 on Hamilton Depression Rating Scale(HDRS) 17-item; * has failed to respond adequately to at least one full course (\>6 weeks) of antidepressant medication or medication intolerant. Exclusion Criteria: * significant head trauma * active abuse of alcohol or illegal substances * current psychotic symptoms * suicide ideation/recent suicide attempts * other DSM-IV Axis I and II psychiatric diagnosis * neurological disorders and contraindications to fMRI (e.g. pace makers, metal implants, pregnancy) or rTMS, or having undergone electroconvulsive therapy in the preceding year.
Conditions Geriatric Disorder, Depression
Phase Not Applicable
Enrollment 19000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

QualGeP (KVALAP) is a quality register in Viken Research network for Geriatric Psychiatry. The objectives of the register are to enhance our knowledge of old persons with severe psychiatric disorders, and to secure an optimal medical evaluation, treatment and care for these patients. The data in the register will be used for quality assurance and for research. Aims: * Quality assurance * Further development of our diagnostic and screening tools * Contributing to improving the treatment, with and without drugs * Contributing to improving the dialogue and collaboration between primary healthcare and hospitals

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Depression and cognition (During admission)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2011-04
Completion: 2030-12
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 19000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Geir Selbaek
Collaborators: Oslo University Hospital, University Hospital, Akershus, Diakonhjemmet Hospital
Principal Investigators:
  • Knut A. Engedal, professor (PRINCIPAL_INVESTIGATOR) - Norwegian Centre for Ageing and Health
Contact Information
Study Contact:
Lisbeth D Høgset, MSc
97582098
Lisebeth.Dyrendal.Hogset@sykehuset-innlandet.no
Kari M Kristiansen, MSc
97761638
kari.kristiansen@aldringoghelse.no
Kari M Kristiansen, MSc
97761638
kari.kristiansen@diakonsyk.no
Old Age Psychiatry Unit, Diakonhjemmet Hospital
Interventions
N/A
Study Locations (1 sites)
Old Age Psychiatry Unit, Diakonhjemmet Hospital, Oslo, 0854 Norway
Eligibility Criteria
Inclusion Criteria: * Patients submitted to geriatric psychiatry units and their relatives who sign the consent form Exclusion Criteria: * Patients and relatives who refuse to sign the consent form
Conditions Chronic and Episodic Headache, Headache ...
Phase Not Applicable
Enrollment 64
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Headache, in its episodic and chronic forms, cannot be considered solely as an isolated neurological symptom, but as a complex condition of a bio-psycho-social nature. While in the episodic form the painful episodes occur intermittently and have a variable impact on daily life, in the chronic form the disease evolves towards persistent pain, with more significant consequences on personal, social and work functioning. The following study protocol aims to investigate in an integrated manner the neurological, cognitive and psychological mechanisms involved in headache, with particular attention to the differences between episodic and chronic forms. The main objective is to assess the neuropsychological profiles and pain response of patients, monitoring their evolution over a period of approximately six months, considering the impact of central sensitisation, personality structure and any psychopathological comorbidities on pain management and treatment adherence. The protocol adopts a multidimensional approach aimed at optimising therapeutic efficacy and improving patients' quality of life, preventing progression to chronicity.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Neuropsychological assessment — Standardized and ad hoc test battery for comprehensive neuropsychological assessment

Primary Outcomes

  • Neuropsychological assessment (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-11-20
Completion: 2028-11-20
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: false
Enrollment: 64 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Centro Neurolesi Bonino Pulejo
Contact Information
Study Contact:
Anna Anselmo, Psychologist
3489266543
anna.anselmo@irccsme.it
Anna Anselmo, Study Principal Investigator
3489266543
anna.anselmo@irccsme.it
Irccs Centro Neurolesi Bonino Pulejo
Interventions
  • Other: Neuropsychological assessment — Standardized and ad hoc test battery for comprehensive neuropsychological assessment
Study Locations (1 sites)
Irccs Centro Neurolesi Bonino Pulejo, Messina, Sicily 98066 Italy
Eligibility Criteria
Inclusion Criteria: * Age between 18 and 60 years; * Diagnosis of chronic or episodic headache; * Patients attending the Headache Outpatient Clinic. Exclusion Criteria: * Presence of severe psychiatric and neurological disorders; * Presence of oncological diseases in terminal stage
Conditions Major Depressive Disorder
Phase PHASE3
Enrollment 165
Locations 30 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Other: Placebo — A substance that is designed to have no therapeutic value
  • Drug: DT120 — A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Primary Outcomes

  • Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (Baseline to Week 6)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-05-10
Completion: 2028-06
Eligibility
Age: 18 Years – 74 Years
Sex: ALL
Volunteers: false
Enrollment: 165 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Definium Therapeutics US, Inc.
Contact Information
Study Contact:
Definium Therapeutics Clinical Trials Info Requests
1-332-282-0479
clinicaltrials@definiumtx.com
Stacy Tierney
501-553-9987
stierney@preferredresearchpartners.com
Preferred Research Partners, Inc.
Raissa Rebollar
949-354-5353
raissar@pnsoc.com
ATP Clinical Research Orange County
Interventions
  • Other: Placebo — A substance that is designed to have no therapeutic value
  • Drug: DT120 — A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Study Locations (30 sites)
Preferred Research Partners, Inc., Little Rock, Arkansas 72211 United States
ATP Clinical Research Orange County, Orange, California 92866 United States
Kadima Neuropsychiatry Institute, San Diego, California 92037 United States
UCSF Department of Neurology, San Francisco, California 94158 United States
Psychedelic Science Institute, Santa Monica, California 90404 United States
Mountain View Clinical Research, Inc, Denver, Colorado 80209 United States
Clinical Neuroscience Solutions, LLC (Jacksonville), Jacksonville, Florida 32256 United States
K2 Medical Research (Maitland), Maitland, Florida 32751 United States
Clinical Neuroscience Solutions, LLC (Orlando), Orlando, Florida 32801 United States
Charter Research, Orlando, Florida 32803 United States
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of MDD per DSM-5 2. Male or female aged 18 to 74 3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration 4. MADRS Total Score ≥26 5. CGI-S Score ≥4 Exclusion Criteria: 1. Certain psychiatric disorders (other than major depressive disorder) 2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder 3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine 4. Any clinically significant unstable illness